[1] 国家食品药品监督管理总局.国家药品不良反应监测年度报告(2016年)[EB/OL].(2017-04-28)[2017-06-01]. http://www.cfda.gov.cn/WS01/CL0844/172167.html.
[2] Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries[J]. Drug safety, 2014, 37(6): 409-419.
[3] Banerjee A K, Okun S, Edwards I R,et al. Patient-reported outcome measures in safety event reporting-PROSPER consortium guidance[J]. Drug Saf, 2013,36(12):1129-1149.
[4] 田怡, 杨悦, 田丽娟. 美国FDA药品风险沟通的发展与启示[J]. 中国药物警戒,2016,13(1): 24-27,31.
[5] 王晓燕,杨悦.欧盟新的药物警戒法规简介与启示[J]. 中国药物警戒, 2013, 10(7): 396-399.
[6] 苏畅,邱家学.欧盟药物警戒额外监测制度简介与启示[J].药物评价研究, 2014, 37(1): 7-10.
[7] European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) [EB/OL]. (2013-06-06)[2016-05-27]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guid-eline/2013/06/WC500144009.pdf.
[8] 严瑾,邵蓉.中英不良反应监测报告内容对比及启示[J].广东药学院学报, 2015, 31(2): 235-239.
[9] Kalaivani M, Kalaiselvan V, Dabhi K, et al. Direct Consumer Reporting of ADRs to PvPI, a Position Paper of Indian Pharmacopoeia Commission[J/OL]. Adv Pharmacoepidemiol Drug Saf, 2015,4(3): 184.
[10] Sten Olsson. New WHO handbook on direct patient reporting[J/OL]. UPPSALA REPORTS,2012,(57):11.
[11] H rmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems[J]. Drug safety, 2015, 38(4): 337-347.
[12] Golomb B A, McGraw J J, Evans M A, et al. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance[J]. Drug Saf, 2007, 30(8): 669- 675.
[13] Ekins-Daukes S, Irvine D, Wise L, et al. The Yellow Card Scheme: evaluation of patient reporting of suspected adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2006,15(S1):S105.
[14] Rolfes L, Hunsel F, Wilkes S, et al. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information[J]. Pharmacoepidemiology & Drug Safety, 2015, 24(2):152.
[15] Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine[J]. Int J Risk Saf Med, 2004,16(1):5-19.
[16] Frankenfeld C. "Serious" and "severe" adverse drug reactions need defining[J]. Bmj, 2004, 329(7465):573.
[17] de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience[J]. Drug Saf, 2008,31(6):515-524.
[18] Egberts T C G, Smulders M, De Koning F H P, et al. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals[J]. BMJ, 1996, 313(7056): 530-531.
[19] The Netherlands Pharmacovigilance Centre Lareb. Gokverslaving en antiparkinsonmiddelen[J].Geneesmiddelenbulletin,2006,40(8):86-87.
[20] The Medical Products Agency. A Swedish registry based cohort study provides strengthened evidence of an association between vaccination with Pandemrix and narcolepsy in children and adolescents[EB/OL].(2011-03-28)[2017-06-03].https://lakemedelsverket.se/english/All-news/NYHETER-2011/A-Swedish-registry-based-cohort-study-provides-strengthened-evidence-of-an-association-between-vaccination-with-Pandemrix-and-narcolepsy-in-children-and-adolescents-/.
[21] 吴桂芝,王春婷,张力. 药品不良反应自发报告系统信息采集内容和方式的分析[J]. 中国药物警戒, 2011,8(10): 596-599.
[22] 边蕾,赵频,杨悦.药物警戒中患者直接报告情况研究[J].中国药物警戒,2013,10(10):609-613. |